TSLA
Tesla
-- 421.060 NVDA
NVIDIA
-- 134.700 PLTR
Palantir
-- 80.550 AMD
Advanced Micro Devices
-- 119.210 QUBT
Quantum Computing
-- 17.620 
NEWS
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Thursday, 19th December at 7:30 am
• Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
• Demonstrated efficacy at 6 months
◦ 71% percent of patients achieved a >30% reduction in the urine protein to creatinine ratio (UP/Cr)
◦ 71% of patients achieved improved or stabilized estimated glomerular filtration rate (eGFR)
• Bremelanotide therapy increased urinary VEGF levels in 37.5% of patients and reduced urinary synaptopodin losses in 36% of patients
CRANBURY, N.J., Dec. 19, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced topline data for the BREAKOUT study. The BREAKOUT study is a Phase IIb, Multicenter, Open-Label, Prospective Study of BREmelanotide in DiAbetic Kidney Disease to Assess the Efficacy in Reducing Urinary PrOtein and Maintaining Podocyte Density and FUncTion.
Thursday, 19th December at 7:30 am
• Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
• Demonstrated efficacy at 6 months
◦ 71% percent of patients achieved a >30% reduction in the urine protein to creatinine ratio (UP/Cr)
◦ 71% of patients achieved improved or stabilized estimated glomerular filtration rate (eGFR)
• Bremelanotide therapy increased urinary VEGF levels in 37.5% of patients and reduced urinary synaptopodin losses in 36% of patients
CRANBURY, N.J., Dec. 19, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced topline data for the BREAKOUT study. The BREAKOUT study is a Phase IIb, Multicenter, Open-Label, Prospective Study of BREmelanotide in DiAbetic Kidney Disease to Assess the Efficacy in Reducing Urinary PrOtein and Maintaining Podocyte Density and FUncTion.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment